Press Release No. 036/KFCP-DIR/PR/IX/19 Jakarta, 16 September 2019 - PT Kalbe Genexine Biologics (KG Bio), a joint venture of Kalbe Farma Tbk (Kalbe), and Genexine, Inc. enters into an exclusive collaboration for HLX10 an immuno-oncology product developed by Shanghai Henlius Biotech, Inc of China. HLX10 is a recombinant humanized anti-programmed cell death (PD-1) monoclonal antibody injection independently developed by Henlius. With the collaboration, KG Bio will be granted exclusive rights to develop and commercialize HLX10 in the South East Asia including Philippines, Indonesia, Malaysia, Singapore, Thailand, Laos, Myanmar, Cambodia, Brunei and Vietnam. `We welcome warmly this...
|
